CTT Pharma and Johns Hopkins University Seek NIH Grant for Smoking Cessation

On January 28, 2025, CTT Pharmaceutical Holdings, Inc. and Johns Hopkins University submitted a proposal for a $15 million NIH grant. This grant will fund clinical trials using CTT's patented technology for smoking cessation. The review process is set to begin in April 2025. The CEO of CTT Pharma, Ryan Khouri, expressed optimism about helping smokers quit, highlighting that 480,000 Americans die each year from smoking-related causes.

CTT's nicotine strips provide a fast-acting alternative to the Nicorette gum, dissolving quickly and using less nicotine per dose. Khouri aims to price these strips competitively. Johns Hopkins will manage the clinical trials in full. Khouri has engaged with FDA and NIH officials and may appear on Fox Business and Bloomberg to discuss the initiative.